title: Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457.
authors: Manuela
authors: M
authors: Mancini
authors: Michela
authors: M
authors: Aluigi
authors: Elisa
authors: E
authors: Leo
authors: Chiara
authors: C
authors: Marcozzi
authors: Fausto
authors: F
authors: Castagnetti
authors: Enza
authors: E
authors: Barbieri
authors: Maria Alessandra
authors: MA
authors: Santucci
mesh_terms: D000818:Animals; D064127:Aurora Kinases; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D006657:Histones / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism*; D051379:Mice; D010879:Piperazines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology*; D003521:Cyclopropanes; D011720:Pyrazoles
chemical_list: D064127:Aurora Kinases; D001549:Benzamides; D006657:Histones; D000068877:Imatinib Mesylate; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D017346:Protein Serine-Threonine Kinases; D011743:Pyrimidines; C484810:tozasertib; D003521:Cyclopropanes; D011720:Pyrazoles